0000000000335829
AUTHOR
Eric Vicaut
showing 8 related works from this author
Étude prospective de l’efficacité et de la tolérance des prothèses auditives à ancrage osseux à peau fermée Alpha dans les surdités profondes unilaté…
2014
But de la presentation La rehabilitation de la surdite unilaterale profonde de l’adulte par un appareillage a ancrage osseux a travers un pilier transcutanee est une solution efficace mais comporte quelques effets adverses cutanes et une faible acceptabilite par les patients. Un appareil a ancrage osseux a peau fermee peut potentiellement permettre la rehabilitation de ces surdites avec moins de morbidite. Le but de cette etude etait d’evaluer les implants Alpha a ancrage osseux transcutane dans cette indication. Materiel et methodes Cette etude prospective a ete conduite dans 2 centres ORL universitaires entre 2010 et 2013 et a permis d’inclure 24 patients adultes (âge moyen 48 ± 12,5, sex…
Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration70 mg/dL After an Ischemic Stroke of Atherosclero…
2020
Background: The TST trial (Treat Stroke to Target) showed the benefit of targeting a low-density lipoprotein cholesterol (LDL-C) concentration of <70 mg/dL in terms of reducing the risk of major cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature. The impact on carotid atherosclerosis evolution is not known. Methods: TST-PLUS (Treat Stroke to Target–Plaque Ultrasound Study) included 201 patients assigned to an LDL-C concentration of <70 mg/dL and 212 patients assigned to a target of 100±10 mg/dL. To achieve these goals, investigators used the statin and dosage of their choice and added ezetimibe as needed. Ultrasonographer…
Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…
2021
Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…
Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk…
2021
Type 1 diabetes mellitus (T1DM) is associated with a high risk of cardiovascular (CV) complications, even after controlling for traditional CV risk factors. Therefore, determinants of the residual increased CV morbidity and mortality remain to be discovered. This prospective cohort of people living with T1DM in France (SFDT1) will include adults and children aged over six years living with T1DM, recruited throughout metropolitan France and overseas French departments and territories. The primary objective is to better understand the parameters associated with CV complications in T1DM. Clinical data and biobank samples will be collected during routine visits every three years. Data from conn…
Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials.
2017
Defining a “higher-risk” population among intermediate-risk patients with pulmonary embolism included in PEITHO http://ow.ly/JM7u30hcSgN
Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.
2020
Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…
OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pa…
2017
International audience